Inside FNIH: Dr. Stacey Adam on Smarter, Human-Based Research
Release Date: 08/10/2025
BioTalk with Rich Bendis
This episode of the BioTalk with Rich Bendis Podcast brings together leaders from industry, academia, and economic development to unpack the vision behind a new life sciences Innovation District anchored in Prince William County. With introductions to NAUGEN, George Mason University’s Institute for Biohealth Innovation, and the Prince William County Department of Economic Development, setting the stage for how each organization contributes to the district’s foundation. The guests talk about the life science assets, research strengths, and translational capabilities that define the district...
info_outlineBioTalk with Rich Bendis
IonQ Vice President and GM of Quantum Platform Matthew Keesan joins BioTalk for a clear look at how they are advancing quantum computing from its home base in the BioHealth Capital Region. He shares the story of IonQ’s Maryland roots and explains quantum computing in straightforward terms for listeners seeking a high-level understanding. The conversation moves into why biohealth leaders should track the hardware race, what distinguishes IonQ’s approach, and how quantum is already being paired with AI to strengthen modeling and analysis. Keesan walks through early use cases showing traction...
info_outlineBioTalk with Rich Bendis
William Hurley, known widely as Whurley, joins BioTalk for a deep look at how quantum computing is moving from theory into practical use across the biohealth landscape. He opens the conversation with an introduction to Strangeworks and explains why the company is focused on making quantum computing more accessible for real-world problem-solving. The discussion explores how quantum could support breakthroughs in genomics and personalized medicine, improve the way clinical trials are modeled, and strengthen manufacturing and supply chain operations. Whurley also talks through the ingredients...
info_outlineBioTalk with Rich Bendis
Secretary Juan Pablo Segura joins BioTalk for a conversation about Virginia’s growing position in the biohealth economy and the statewide strategy behind it. He outlines the significance of the new partnership with AstraZeneca, Lilly, and Merck, including up to $120 million in private investment to create a workforce development center and expand the Commonwealth’s life sciences capacity. Segura talks through how Virginia approaches company recruitment, what investors are responding to, and why the state is seeing increased interest from biomanufacturing and advanced R&D companies. He...
info_outlineBioTalk with Rich Bendis
This episode brings together three leaders working at the intersection of pediatric innovation, health security, and early-stage commercialization. Kolaleh Eskandanian, Program Director of SPARK, is joined by founders Dori Jones of AcQumen Medical and Jugal Suthar of Vesynta for a conversation about advancing breakthrough solutions for children. They discuss the mission behind the BARDA-funded SPARK for Innovations in Pediatrics Hub at Children's National Hospital, the challenges of developing technologies for pediatric populations, and the impact of public-private partnerships in moving...
info_outlineBioTalk with Rich Bendis
In this episode of BioTalk, CEO Gerard Eldering explains how Perfusion Medical is addressing a problem that trauma physicians and military medics have been struggling with for decades: capillary compression. Perfusion Medical is developing a drug aimed at treating hemorrhagic shock and other ischemic conditions. PM‑208 is a novel IV therapeutic designed to restore capillary blood flow, resolve ischemia, and protect vital organs. The team has advanced this work with $19 million in Department of Defense funding. He describes the scale of the unmet need, why PM‑208 is both organ- and...
info_outlineBioTalk with Rich Bendis
In this episode of BioTalk, Rich Bendis sits down with Councilman Brian Knudsen, Jamie Schwartz of UNLV, and Vance Farrow from the Nevada Governor’s Office of Economic Development to spotlight the rapid emergence of Southern Nevada as a rising force in the biohealth landscape. The conversation covers the launch of the $10 million BioHealth Innovation Challenge, the Desert Forge Venture Fund, and the revitalization of BioTech Vegas, all designed to attract industry anchors, fuel early-stage startups, and cultivate a thriving innovation ecosystem. They also explore how strong collaboration...
info_outlineBioTalk with Rich Bendis
In this episode of BioTalk with Rich Bendis, Harry Coker, Jr., Secretary of the Maryland Department of Commerce, joins the podcast to discuss Maryland’s rising momentum as a global biohealth and technology leader. Secretary Coker shares his unique journey from the CIA, NSA, and White House to leading Maryland’s economic development strategy, highlighting the state’s strengths in life sciences, its appeal to global investors, and the importance of public-private partnerships in accelerating innovation. Topics include Maryland’s recent recognition as a Top 3 biopharma hub, the...
info_outlineBioTalk with Rich Bendis
Building Maryland’s BioHealth Future: Maryland Commerce’s Stefanie Trop on Growing the Life Sciences Sector In this episode of BioTalk with Rich Bendis, Stefanie Trop, Ph.D., Director of Life Sciences at the Maryland Department of Commerce joins the conversation to discuss Maryland’s position as a leading life sciences hub. Stefanie shares how the Department of Commerce supports company attraction and growth through programs like Global Gateway, and how it’s amplifying the state’s recent #3 biopharma hub ranking. The discussion also explores Maryland’s unique ecosystem, including...
info_outlineBioTalk with Rich Bendis
In this episode of BioTalk, Rich Bendis welcomes Dr. Stacey Adam, Vice President of Science Partnerships, Translational Science at the Foundation for the National Institutes of Health (FNIH), to discuss how public-private partnerships are advancing scientific innovation. Dr. Adam introduces the mission of FNIH and its unique role in bridging government, industry, and academia to accelerate biomedical progress. She highlights the Validation and Qualification Network (VQN), a new initiative working to overcome barriers to the adoption of New Approach Methodologies (NAMs) and explains how...
info_outlineIn this episode of BioTalk, Rich Bendis welcomes Dr. Stacey Adam, Vice President of Science Partnerships, Translational Science at the Foundation for the National Institutes of Health (FNIH), to discuss how public-private partnerships are advancing scientific innovation. Dr. Adam introduces the mission of FNIH and its unique role in bridging government, industry, and academia to accelerate biomedical progress. She highlights the Validation and Qualification Network (VQN), a new initiative working to overcome barriers to the adoption of New Approach Methodologies (NAMs) and explains how cross-sector collaboration is driving its early success. The conversation explores the long-term vision of the VQN, the global perspectives shaping its approach, and how it fits into the broader NIH Complement-ARIE initiative. Dr. Adam also reflects on the significance of being headquartered in the BioHealth Capital Region and how it supports the Foundation’s mission.
Editing and post-production work for this episode was provided by The Podcast Consultant.
Guest Bio
Dr. Stacey Adam is Vice President of Science Partnerships at the Foundation for the NIH (FNIH), where she leads major public-private partnerships including the RECOVER-Treating Long COVID initiative, multiple Biomarkers Consortium projects, the Accelerating Medicines Partnerships (AMPs), and the Lung-MAP clinical trial. She also leads efforts to design new public-private partnerships focused on pediatric medical devices, cancer systems biology, and the advancement of New Approach Methodologies (NAMs) through the Validation and Qualification Network. Previously, Dr. Adam worked at Deloitte Consulting and completed a postdoctoral fellowship at Stanford University School of Medicine. She holds a PhD in Pharmacology with a Certificate in Mammalian Toxicology from Duke University.